Open Access


Read more
image01

Online Manuscript Submission


Read more
image01

Submitted Manuscript Trail


Read more
image01

Online Payment


Read more
image01

Online Subscription


Read more
image01

Email Alert



Read more
image01

Original Research Article | OPEN ACCESS

Synthesis of new hybrid quinazoline compounds as antiproliferative agents for breast and colon cancer treatment

Marwa F Ahmed1 , Amany S Khalifa2, Emad M Eed3

1Department of Pharmaceutical Chemistry, College of Pharmacy, Taif University, Taif 21944, Saudi Arabia; 2Department of Pharmaceutics, College of Pharmacy, Taif University, Taif 21944, Saudi Arabia; 3Department of Clinical Laboratories Sciences, College of Applied Medical Sciences, Taif University, Taif 21944, Saudi Arabia.

For correspondence:-  Marwa Ahmed   Email: marwafarag80@tu.edu.sa

Accepted: 15 March 2022        Published: 30 April 2022

Citation: Ahmed MF, Khalifa AS, Eed EM. Synthesis of new hybrid quinazoline compounds as antiproliferative agents for breast and colon cancer treatment. Trop J Pharm Res 2022; 21(4):833-839 doi: 10.4314/tjpr.v21i4.21

© 2022 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To evaluate newly synthesized fuoryl quinazoline derivatives for antitumor efficacy.
Methods: Fuoryl quinazoline derivatives were synthesized and the structures of the synthesized compounds were characterized using standard techniques. The 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) technique was used to assess the anti-proliferative properties of the synthesized derivatives in vitro.
Results: All quinazoline compounds displayed cytotoxic activity against breast and colon cancer cell lines to varying degrees. Compound IXa with acetohydrazide moiety was the most effective on MCF7 and HCT116 cell lines, with half-maximal inhibitory concentration (IC50) values of 16.70 and 12.54 µM, respectively.
Conclusion: N'-benzylidene-2-((2-(furan-2-yl) quinazolin-4-yl) oxy) acetohydrazide IXa showed the strongest anti-proliferative activity against MCF-7 and HCT116 human cancer cell lines.

Keywords: Quinazoline, Antitumor, Acetohydrazide, Carbothioamide

Impact Factor
Thompson Reuters (ISI): 0.6 (2023)
H-5 index (Google Scholar): 49 (2023)

Article Tools

Share this article with



Article status: Free
Fulltext in PDF
Similar articles in Google
Similar article in this Journal:

Archives

2024; 23: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10. 
2023; 22: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12. 
2022; 21: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12. 
2021; 20: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12. 
2020; 19: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12. 
2019; 18: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12. 
2018; 17: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12. 
2017; 16: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12. 
2016; 15: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12. 
2015; 14: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12. 
2014; 13: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12. 
2013; 12: 
1,   2,   3,   4,   5,   6. 
2012; 11: 
1,   2,   3,   4,   5,   6. 
2011; 10: 
1,   2,   3,   4,   5,   6. 
2010; 9: 
1,   2,   3,   4,   5,   6. 
2009; 8: 
1,   2,   3,   4,   5,   6. 
2008; 7: 
1,   2,   3,   4. 
2007; 6: 
1,   2,   3,   4. 
2006; 5: 
1,   2. 
2005; 4: 
1,   2. 
2004; 3: 
1. 
2003; 2: 
1,   2. 
2002; 1: 
1,   2. 

News Updates